European Oncology
Real-world data solutions built for the complexity of European oncology research.
Your trusted partner for real-world oncology insights across Europe
Oncology research in Europe presents many unique challenges.
Variations in treatment practices across countries, difficulties accessing diverse patient samples, and inconsistent data quality across institutions make it hard to produce reliable, generalizable evidence of treatment value.
From comprehensive datasets to smarter study designs, our European oncology solutions bring clarity to your research, accelerating timelines, strengthening submissions, and enabling better patient outcomes in oncology care.
TherapyMonitor™
Timely, representative insight into real-world oncology care in Europe.
Built from the latest longitudinal physician-supplied data across Europe, TherapyMonitor™ delivers comprehensive analyses of cancer care in real clinical practice.
Working closely with medical experts and pharmaceutical leaders, our Europe-based team of analysts tailors report specifications to your precise study objectives in oncological and rare-disease indications.
Offering complete, curated data on disease prevalence, treatment patterns, and care dynamics across the continent, TherapyMonitor™ data is carefully collected, validated, and fully anonymized to meet the highest regulatory standards, ensuring accuracy, quality, and confidence in every insight.
External Control Arms
Accelerate your research with fit-for-purpose real-world patient cohorts.
TriNetX External Control Arms (ECAs) provide a proven, regulation-ready methodology to create real-world comparison cohorts without the high costs and lengthy timelines of traditional methods.
Epidemiological services
Unlock stronger decision-making, targeting, sampling, and understanding of health outcomes with our evidence-based analysis and representative data.
Backed by our strong record of successful HTA submissions, depth of experience, and partnerships with physicians and healthcare providers, you can be confident you’re in good hands.
Wish to participate in a TherapyMonitor™ project?
If you’re an EU physician looking to participate in an ongoing TherapyMonitor™ project, we’d love to hear from you.
Any time and contributions you’re able to offer will be fairly rewarded with monetary reimbursement, as well as opportunities to collaborate on resulting publications.
Additionally, we’ll be here to support you with the data entry process at every stage, providing well-structured eCRFs and prompt responses to any questions or technical issues you might have.
How you’ll be supported
We provide physicians with several supporting documents specifically tailored to each individual project. These include:
- Data entry instructions
- Documentation on the legality of our retrospective methodology
- Standardized invitation, follow-up, remuneration, and thank-you emails
- Project synopsis for quick insights
- Troubleshooting instructions, which may range from quick fixes to step-by-step guidance with screenshots
- Data cleaning processes performed by our monitors (internal documents such as guidelines, training presentations, and updated treatment guides are not shared with physicians)
Want to learn more?
Explore our latest insights
Big data isn’t always the right data. Learn how to assess whether a dataset is truly fit for your research question, because data fitness is about the right elements for the right cohort, not dataset size or reputation.
EHR data is one of the richest sources for real-world research, but it was never actually designed for it. This video covers the opportunities, the pitfalls, and the mindset needed to get the most out of it.
Misaligned definitions don’t just complicate analysis; they produce misleading results. Learn why harmonized definitions are essential for multi-site RWD studies and what it takes to make them stand up to scientific and regulatory scrutiny.
At ISPOR 2026, we presented posters addressing outcomes in relapsed/refractory DLBCL, and introducing a reproducible method for generating population estimates robust enough to stand up in HTA and regulatory submissions.
Current projects
| Indication | Current countries |
|---|---|
| Chronic Lymphocytic Leukemia (CLL) Second Line Therapy (2L+) | Germany, Spain |
| Defuse Large B-cell Lymphoma (DLBCL) | Germany |
| Estrogen receptor-positive (ER+), HER2-negative (HER2-), Breast Cancer | Germany |
| Newly diagnosed multiple myeloma (NDMM), Relapsed/refractory multiple mylenoma (RRMM) | Germany, Spain |
| Renal Cell Carcinoma (RCC) | Germany |
| Urothelial Cancer | Germany |
Contact TriNetX
Need to reach out? We’re here to help.
"*" indicates required fields
